Haemonetics Corporation announced the election of Ellen M. Zane to its Board of Directors. Zane is a nationally renowned health care leader with more than 30 years of experience in hospitals and healthcare systems.
Zane led the turnaround of Tufts Medical Center and Floating Hospital for Children in Boston, where she retired as President and Chief Executive Officer in 2011 and currently serves as Vice Chair of the Board of Trustees. She returned the organization to financial stability and strengthened its academic relationships and community physician networks to deliver high-quality, cost-efficient and patient-centered care amid rapid change in the healthcare industry.
From 1994 to 2004, Zane was Network President of Partners HealthCare System, Inc., where she developed one of the largest physician networks in the country. Prior to this, she was Chief Executive Officer of Quincy Hospital.
Zane serves on the board of global medical technology leader Boston Scientific Corporation, as well as the boards of Brooks Automation and Fiduciary Trust Company. She is also a former director of PAREXEL International Corporation. Zane previously served on Haemonetics’ Board of Directors from 2012-2016.
“We are pleased to welcome Ellen back to our Board. Her broad expertise in health systems and physician enterprises will bring valuable insights across the company’s growth businesses, especially our Hospital business unit,” said Richard J. Meelia, Chairman of Haemonetics’ Board of Directors. “The Board is committed to renewal in support of Haemonetics’ turnaround. Ellen is the fourth director to join in the past 18 months and will add to the Board’s strong mix of operational and strategic experience as the company transforms to pursue accelerated growth.”
Zane earned a Bachelor of Arts degree from George Washington University and a Master of Arts degree from The Catholic University of America, and holds honorary doctorate degrees from Bentley University, Stonehill College and Curry College. She is on the faculty at Tufts University School of Medicine and The Harvard T. H. Chan School of Public Health.
Source: Haemonetics
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.
